Works matching IS 00155691 AND DT 2022 AND VI 157 AND IP 4

Results: 15

Untitled.

Published in:

Folia Pharmacologica Japonica, 2022, v. 157, n. 4, p. 213, doi. 10.1254/fpj.22030

By:

Masato Tsutsui;
Hiroshi Watanabe

Publication type:

Article

Pharmacological actions of anifrolumab (Saphnelo®) and clinical trial results as a treatment for systemic lupus erythematosus.

Published in:

Folia Pharmacologica Japonica, 2022, v. 157, n. 4, p. 271, doi. 10.1254/fpj.22026

By:

Takeshi Ueha;
Masaki Kusuda;
Shoko Shibata;
Masako Hirata;
Naoko Ozaki

Publication type:

Article

Untitled.

Published in:

Folia Pharmacologica Japonica, 2022, v. 157, n. 4, p. 232, doi. 10.1254/fpj.22025

By:

Susumu Jitsuki;
Tomoyuki Miyazaki

Publication type:

Article

Untitled.

Published in:: Folia Pharmacologica Japonica, 2022, v. 157, n. 4, p. 280, doi. 10.1254/fpj.22024
Publication type:: Article

Untitled.

Published in:

Folia Pharmacologica Japonica, 2022, v. 157, n. 4, p. 248, doi. 10.1254/fpj.22023

By:

Hisaharu Yamada;
Kohei Kikkawa

Publication type:

Article

Treatment of COVID-19.

Published in:

Folia Pharmacologica Japonica, 2022, v. 157, n. 4, p. 214, doi. 10.1254/fpj.22019

By:

Kazuhiro Yatera

Publication type:

Article

Role of NO-cGMP-PKG axis in pulmonary arterial hypertension.

Published in:

Folia Pharmacologica Japonica, 2022, v. 157, n. 4, p. 221, doi. 10.1254/fpj.22018

By:

Hiroshi Watanabe

Publication type:

Article

New trend in genotoxicity research taking into account genome instability.

Published in:

Folia Pharmacologica Japonica, 2022, v. 157, n. 4, p. 265, doi. 10.1254/fpj.22015

By:

Kei-ichi Sugiyama;
Kenichi Masumura

Publication type:

Article

Vascular hyperpermeable molecules potentially contributing to the development of pulmonary edema in sepsis-associated ARDS.

Published in:

Folia Pharmacologica Japonica, 2022, v. 157, n. 4, p. 229, doi. 10.1254/fpj.22013

By:

Hattori, Kohshi;
Matsuda, Naoyuki;
Hattori, Yuichi

Publication type:

Article

A novel ligand for chemogenetic receptors, Deschloroclozapine, enables rapid and selective modulation of neuronal activity and behavior in living animals.

Published in:

Folia Pharmacologica Japonica, 2022, v. 157, n. 4, p. 233, doi. 10.1254/fpj.22012

By:

Yuji Nagai

Publication type:

Article

CRMP2 binding compound accelerates functional recovery from central nervous system damage.

Published in:

Folia Pharmacologica Japonica, 2022, v. 157, n. 4, p. 244, doi. 10.1254/fpj.22011

By:

Susumu Jitsuki

Publication type:

Article

Optical inactivation of molecular functions in vivo by chromophore-assisted light inactivation.

Published in:

Folia Pharmacologica Japonica, 2022, v. 157, n. 4, p. 238, doi. 10.1254/fpj.22009

By:

Kiwamu Takemoto

Publication type:

Article

Challenges in drug discovery research and the effects of SGLT2 inhibitor against diabetic kidney disease.

Published in:

Folia Pharmacologica Japonica, 2022, v. 157, n. 4, p. 249, doi. 10.1254/fpj.22008

By:

Naoki Kojima

Publication type:

Article

Challenges in kidney disease: therapeutic potential of bardoxolone methyl.

Published in:

Folia Pharmacologica Japonica, 2022, v. 157, n. 4, p. 261, doi. 10.1254/fpj.22007

By:

Kengo Yamawaki

Publication type:

Article

Tolvaptan, a vasopressin V<sub>2</sub> receptor antagonist, is the world's first approved drug for treatment of autosomal dominant polycystic kidney disease (ADPKD).

Published in:

Folia Pharmacologica Japonica, 2022, v. 157, n. 4, p. 254, doi. 10.1254/fpj.22006

By:

Yoshihisa Yamada;
Hiroyuki Fujiki;
Hiroshi Mizuguchi;
Yukinobu Takeshita;
Katsuji Hattori;
Koji Ohmoto;
Miki Aihara;
Keisuke Nagano;
Yoshimasa Isakar;
Miho Yamamoto;
Yoshitaka Yamamura

Publication type:

Article